about
Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseasesNeed for a paradigm shift in therapeutic approaches to CNS injuryIs Multiple Sclerosis an Autoimmune Disease?Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating DiseaseNHE4 is critical for the renal handling of ammonia in rodents.Tissue kallikrein permits early renal adaptation to potassium load.IVIg treatment reduces catalytic antibody titers of renal transplanted patientsQuantitative PCR analysis of DNA aptamer pharmacokinetics in mice.Autoantibodies with enzymatic properties in human autoimmune diseases.Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosisA single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis.Abbreviated exposure to hypoxia is sufficient to induce CNS dysmyelination, modulate spinal motor neuron composition, and impair motor development in neonatal miceA role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytesA natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders.Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosisHigh-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance.PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor.Pathophysiology of catalytic antibodies.Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.CD8(+) T cells in multiple sclerosis.The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.Polyclonal and monoclonal antibodies in clinic.Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.Proteolytic antibodies activate factor IX in patients with acquired hemophilia.Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.A Comparison of Human Natural Monoclonal Antibodies and Aptamer Conjugates for Promotion of CNS Remyelination: Where Are We Now and What Comes Next?Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficienciesADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
P50
Q26860077-F01310AD-2112-4607-83CE-D31D6135234FQ27025042-68D6827A-38B6-4F30-B7E9-5E4DCC756C25Q27496011-E02325BF-3319-454B-AEC5-39041D396764Q28080515-648FC6A8-2218-41F5-930A-18EA3CD04523Q33882811-77369D79-AB01-4F9E-8C98-B2F424C881BFQ34067976-17B05D60-09EA-4D07-BBD8-AF2B5F640B76Q34962680-E8EE00CF-97F5-4CDF-AA09-2501910446D3Q34976853-F8861DE4-B872-4342-99ED-900312655DCBQ35214200-55823F0D-9B58-4256-93D0-8F6C0C0C8AB5Q35231795-C7964322-958D-4C32-A1CD-192848D4C924Q35564304-85244AC8-FA30-4424-BCE5-C585AAB56920Q35644564-1824F503-18AE-40BD-8A3E-68C947B0502AQ35829158-EFA82E5B-CFDC-491A-9960-FFA7F6637E39Q35923499-813A33D6-7F82-4347-A47F-4750A15C4408Q35940683-774B6C2B-3F30-47CD-9293-1B0A7A89C349Q35977321-01792652-7EA3-43F2-953B-88A30FD1DB90Q36158112-342AC6AF-6F61-4305-ACDF-18606B077821Q36190666-5D8B7446-D56D-4433-AAF9-DC6E1EBE2E08Q36374328-4DE6EF5E-C99E-4B4B-AF0F-D64E4088A94EQ36465309-FD5EFD87-FB76-4990-BEFF-1C5BD491267AQ36805943-7AE7BF7F-B3B9-4BEC-933E-5D209B813E43Q36905946-A8701F28-21E1-4374-B7E6-ABA6FC9E0BB8Q37374547-02BA381C-482D-4F1E-B66B-9E3B6287945AQ37540582-FF16DF87-0913-42F8-97CC-4EF2F3FB9EE2Q37591260-30CA2F58-CDC6-4891-B132-429FED913C7BQ38111421-A94FB6D0-95E1-4599-AAC0-888A29D5A2DDQ38137827-0B49678C-49E3-49FB-91F8-A97A1782BBEEQ38590198-6F02BE6F-0892-412E-8C19-9BE81550421FQ45862578-16255B74-454F-49DC-9AD0-E9C1781A69BCQ45865445-030EA370-B59F-4AAC-A839-C11580E3F025Q45874085-8F29C912-33E7-4B65-8AE4-F5DAC27CC0F7Q45886858-A21A5595-E864-4BD1-BB92-C209938513BCQ49820777-5307EC48-CB78-4532-908E-13604184684DQ57217676-D1295E2F-777C-468A-A41B-2E59A5B9B877Q94503511-6F419110-A37A-4957-8B80-B93CFD554238
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bharath Wootla
@ast
Bharath Wootla
@en
Bharath Wootla
@es
Bharath Wootla
@nl
Bharath Wootla
@sl
type
label
Bharath Wootla
@ast
Bharath Wootla
@en
Bharath Wootla
@es
Bharath Wootla
@nl
Bharath Wootla
@sl
prefLabel
Bharath Wootla
@ast
Bharath Wootla
@en
Bharath Wootla
@es
Bharath Wootla
@nl
Bharath Wootla
@sl
P1053
E-5882-2015
P106
P108
P31
P3829
P496
0000-0001-7522-1121